home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

3.670 +0.040 (+1.10%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 29, 2024

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 29, 2024

Via Benzinga

Crude Oil Moves Higher; Best Buy Posts Upbeat Earnings ↗

February 29, 2024

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded down 0.16% to 38,884.96 while the NASDAQ rose 0.38% to 16,008.19. The...

Via Benzinga

Topics Stocks

Why Enveric Biosciences Stock Is Soaring ↗

February 29, 2024

Enveric said it could be eligible to receive future development and sales milestone payments and execution fees for the three licenses, which in total could add up to $200 million, assuming certain...

Via Benzinga

Nasdaq Gains 100 Points Following PCE Data ↗

February 29, 2024

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.07% to 38,923.11 while the...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 29, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

February 29, 2024

It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning!

Via InvestorPlace

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

February 29, 2024

From Enveric Biosciences

Via Business Wire

EXCLUSIVE: Enveric Biosciences Announces Non-Binding Deals To License Out Three Types of Drug Compounds ↗

February 29, 2024

Via Benzinga

Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB

February 28, 2024

Via AB Newswire

Topics Intellectual Property

Enveric Biosciences Sells Cancer Patents As It Paves Way For Mental Health Treatments ↗

February 23, 2024

Enveric Biosciences Inc. has announced the sale of a cancer-related patent portfolio, including patents and pending applications in several countries, focusing on cannabidiol as a treatment for cancer....

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 23, 2024

Via Benzinga

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

February 23, 2024

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds ↗

February 21, 2024

Enveric Biosciences announced discovery of multiple compounds using its Psybrary platform and AI system. These compounds broaden their range of mental health treatments.

Via Benzinga

Topics Artificial Intelligence

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

February 21, 2024

From Enveric Biosciences

Via Business Wire

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗

January 12, 2024

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Via Benzinga

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond ↗

January 10, 2024

The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health...

Via Benzinga

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗

January 07, 2024

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

Via Benzinga

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

January 03, 2024

From Enveric Biosciences

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 01, 2024

Via Benzinga

Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 29, 2023

Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a December 2023 business update.

Via Benzinga

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

December 29, 2023

From Enveric Biosciences

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 28, 2023

Via Benzinga

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

December 28, 2023

From Enveric Biosciences

Via Business Wire

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

December 27, 2023

From Enveric Biosciences

Via Business Wire

5 Biotech stocks tapping into unmet mental health treatment needs

December 20, 2023

Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com